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With the advent of prenatal sonography, fetal overgrowth
can be easily detected. Prenatal-onset overgrowth can be
secondary to normal variants of familial tall stature, familial
rapid maturation, diabetic macrosomia, and congenital nesi-
dioblastosis, or prenatal-onset overgrowth can be primary due
to pathological overgrowth disorders. This article provides
a comprehensive review of the prenatal findings and the
genetic diagnosis of some pathological prenatal-onset over-
growth disorders, such as Simpson-Golabi-Behmel syndrome,
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Simpson-Golabi-Behmel syndrome (SGBS) is an X-linked
recessive disorder. Simpson et al [1] first described two
maternal male cousins with macrocephaly, coarse face, broad
hands, dysplastic fingernails, and apparently normal intelli-
gence. Behmel et al [2] later reported a similar condition in
a sibship of several affected males with additional findings that
included congenital heart defects, polydactyly, and a high
infant mortality rate. Golabi and Rosen [3] also described
a family with several affected males with internal organ
malformations who died early. Neri et al [4] described an
Italian family with three affected males with similar anomalies
as previously reported by Simpson et al [1], Behmel et al [2],
and Golabi and Rosen [3] and coined the eponym “Simpson-
Golabi-Behmel syndrome”.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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coarse face, macrocephaly, macrosomia, macroglossia, hyper-
telorism, dental malocclusion, palatal abnormalities, supernu-
merary nipples, cryptorchidism, hypospadias, congenital heart
defects, diaphragmatic hernia, polydactyly and brachydactyly
of the hands, cutaneous syndactyly of the fingers and toes,
hypoplasia of finger nails, vertebral segmental defects, renal
dysplasia/nephromegaly, diastasis recti/umbilical hernia,
enlarged internal organs, and an increased risk (10%) of
developing embryonal tumors such as Wilms tumor, hepato-
blastoma, adrenal neuroblastoma, gonadoblastoma, and hepa-
tocellular carcinoma [1e6].
SGBS type 1 (SGBS1; OMIM 312870) is a milder form of
SGBS. SGBS type 2 (SGBS2; OMIM 300209) is a more
severe form of SGBS [7e9]. SGBS1 is caused by a deletion or
mutation in the GPC3 gene (OMIM 300037), which maps to
Xq26 [10]. SGBS2 has been associated with mutations in the
CXORF5 gene (OMIM 300170), which maps to Xp22 [9]. The
GPC3 gene encodes glypican 3, which acts as a negative
regulator of Hedgehog signaling during development, and
loss-of-function mutations in the GPC3 gene result in the
hyperactivation of Hedgehog signaling that ultimately result in
overgrowth and cancer [11]. The CXORF5 gene or OFD1 gene
encodes chromosome X open reading frame 5 (CXORF5)
protein, which is required for the formation of primary cilia
and left-right axis specification [12e14]. Loss-of-function
mutations in the CXORF5 gene are associated with X-linked
dominant oral-facial-digital syndrome type 1 (OFD1; OMIM
311200) [12,13,15], X-linked recessive SGBS2 [9], and X-
linked recessive Joubert syndrome type 10 (JBTS10; OMIM
300804) [16]. The detection rate of mutations and deletions in
the GPC3 gene ranges from 37e70.3% in patients with SGBS
[17e19]. Veugelers et al [20] reported the deletion of the
GPC3-GPC4 gene cluster in one family with SGBS. GPC4
(OMIM 300168) maps to Xq26 centromeric to GPC3 and
encodes glypican 4, which plays a role in the control of cell
division and growth regulation [20]. Recently, Waterson et al
[21] reported the duplication of the GPC4 gene in the family
that was initially described by Golabi and Rosen [3] and
suggested that the duplication of GPC4 may be the cause of
SGBS.
Fetuses with SGBS may prenatally manifest with macro-
somia, polyhydramnios, elevated maternal serum a-fetopro-
tein (MSAFP), cystic hygroma, hydrops fetalis, increased
nuchal translucency (NT), craniofacial abnormalities, viscer-
omegaly, renal anomalies, congenital diaphragmatic hernia,
polydactyly, and a single umbilical artery [7,22e26]. Chen
et al [22] reported three affected males with SGBS in a family,
and all of these individuals were later found to have the GPC4
duplication [21]. The first case had an elevated MSAFP level
at 22 weeks of gestation. Prenatal ultrasound at 24 weeks of
gestation revealed congenital diaphragmatic hernia, cystic
hygroma, and cystic ureters/kidneys. Amniocentesis revealed
a 46,XY karyotype. The second case was diagnosed with
polyhydramnios at 18 weeks of gestation, and prenatal ultra-
sound showed congenital diaphragmatic hernia and poly-
dactyly. Amniocentesis revealed a 46,XY karyotype. The thirdcase was terminated at 21 weeks of gestation and demon-
strated an elevated MSAFP level, cystic hygroma, craniofacial
anomalies, congenital diaphragmatic hernia, and a single
umbilical artery. Hughes-Benzie et al [23] reported an elevated
MSAFP level at 17 weeks of gestation, macrosomia at 19
weeks of gestation, and polyhydramnios at 28 weeks of
gestation in a male fetus affected with SGBS. This case also
demonstrated a GPC3 deletion at the 3’ end of exon 1 [27].
Yamashita et al [24] reported macrosomia, severe poly-
hydramnios, large liver, and remarkably enlarged kidneys at
29 weeks of gestation in a male fetus affected with SGBS. The
karyotype was 46,XY. Li and McDonald [25] reported an
abnormal NT in the first trimester, an elevated MSAFP level at
16 weeks of gestation, macrosomia, polyhydramnios, cleft lip
and palate, and an abnormal skull at 30 weeks of gestation in
a male fetus affected with SGBS. The fetus also demonstrated
a GPC3 mutation in exon 2 (c.194_206 del) (p.cys65fs).
Weichert et al [26] reported a 1-megabase microdeletion in
Xq26.2 that encompassed the GPC3 gene in a fetus with
SGBS. The associated prenatal findings in that case included
markedly increased NT in the first trimester, macrocephaly,
asymmetric bilateral mild ventriculomegaly, down-turned
corners of a permanently open mouth, low-set ears, flat
facial profile, macrosomia, and polyhydramnios at 22 weeks of
gestation. Terespolsky et al [7] reported the case of four
maternally related male cousins with SGBS2, which was
confirmed to be associated with the SGBS2 locus at Xp22 by
linkage analysis [8]. In their report, one male fetus was
diagnosed with a renal abnormality on prenatal ultrasound,
another male fetus was diagnosed with polyhydramnios at 22
weeks of gestation, and hydrops fetalis was noted in all three
liveborn males at birth.
In instances of fetal overgrowth and polyhydramnios in
association with other abnormalities, such as congenital dia-
phragmatic hernia, increased NT, visceromegaly, renal
anomalies, postaxial polydactyly, single umbilical artery, and
elevated MSAFP, a differential diagnosis of SGBS should be
considered. Examination of the mother for evidence of the
mild SGBS phenotype, examination of the male family
members who demonstrate a positive SGBS phenotype,
mutational analysis of GPC3, GPC4, and CXORF5, and array
comparative genomic hybridization (aCGH) analysis of
genomic imbalance in Xp22 or Xq26 are helpful for genetic
diagnosis and counseling.
Sotos syndrome
Sotos syndrome (OMIM 117550) is an autosomal dominant
disorder. Sotos et al [28] first described five children with
overgrowth, advanced bone age, acromegalic features, high-
arched palate, prominent jaw, and mental retardation. Cole
and Hughes [29] suggested that the characteristic facial
appearance, learning disabilities, and childhood overgrowth
are the major diagnostic criteria for Sotos syndrome. Maroun
et al [30] first reported a 4-year-old girl with Sotos syndrome
and a 46,XX,t(5;15)(q35;q22) karyotype and suggested that
5q35 is the site of the gene that determines Sotos syndrome.
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Sotos syndrome and a 46,XX,t(5;8)(q35;q24.1) karyotype and
proposed that the gene responsible for Sotos syndrome is
located at 5q35. Kurotaki et al [32] subsequently identified
NSD1 as the gene that is disrupted by the 5q35 breakpoint via
positional cloning.
Sotos syndrome is characterized by its cardinal features (
90%) that consists of a characteristic facial appear-
ancedincluding a high broad forehead, an inverted pear-like
head, sparse frontotemporal hair, molar flushing, down-
slanting palpebral fissures, a long face, and a pointed
chindlearning disabilities, and overgrowth; the major features
( 15%) include advanced bone age, cranial abnormalities on
diagnostic computed tomographic scans and magnetic reso-
nance imaging, poor feeding during infancy, neonatal jaun-
dice, hypotonia, seizures, scoliosis, cardiac anomalies, renal
anomalies, joint laxity, pes planus, and a slightly increased risk
(2.2% or < 3%) of developing neoplasms such as sacro-
coccygeal teratoma, neuroblastoma, presacral ganglioma,
acute lymphoblastic leukemia, small cell lung cancer, Wilms
tumor, hepatocellular carcinoma, cardiac/ovarian fibroma, and
germ cell tumor [33e36].
Sotos syndrome is caused by a deletion or mutation in the
NSD1 gene (OMIM 606681), which maps to 5q35 [32,37,38].
The NSD1 gene encodes nuclear receptor set domain protein 1,
which enhances androgen receptor transactivation [39]. At
least 90% of patients with Sotos syndrome have NSD1
abnormalities [40,41]. Intragenic mutations cause 27e93% of
non-Japanese Sotos syndrome cases and about 12% of Japa-
nese Sotos syndrome cases, and 5q35 microdeletions cause
about 50% of Japanese cases and about 10% of non-Japanese
Sotos syndrome cases [36,40e51]. However, in about 10% of
classic cases of Sotos syndrome, NSD1 abnormalities are not
identified [41]. Most cases with Sotos syndrome arise de novo,
and familial Sotos syndrome with vertical transmission occurs
in < 10% of cases with Sotos syndrome [41,48,52].
Fetuses with Sotos syndrome may prenatally manifest with
increased NT, an increased risk of Down syndrome on
maternal serum screening, macrocephaly, polyhydramnios,
fetal overgrowth, renal abnormalities, and central nervous
system abnormalities [53e55]. Chen et al [53] reported
macrocephaly, an irregular skull shape, ventriculomegaly,
corpus callosum hypoplasia, enlarged cistern magna, over-
growth, unilateral hydronephrosis, and polyhydramnios on
prenatal ultrasound in the third trimester in a fetus with
familial Sotos syndrome. The pregnancy was associated with
an abnormal maternal serum screen that indicated a Down
syndrome risk of 1/212 and a 46,XY karyotype for the fetus.
Thomas and Lemire [54] reported macrocephaly and an
increased Down syndrome risk of 1/8 on the maternal serum
screen at 17 weeks of gestation, and macrosomia and poly-
hydramnios at 34 weeks of gestation in a fetus with familial
Sotos syndrome and a frameshift mutation (5712delC) in the
NSD1 gene. Schou et al [55] reported increased NT (7 mm)
and large for date on prenatal ultrasound in a fetus with a de
novo mutation in the NSD1 gene. Schaefer et al [56] and
Gusma˜o Melo et al [57] reported abnormal neuroimagingfindings in all patients with Sotos syndrome. The reported
neuroimaging findings included enlargement of the lateral
ventricles, trigones, and occipital horns, corpus callosum
hypoplasia, persistence of cavum septum pellucidum, cavum
vergae, and cavum velum interpositum, enlarged cisterna
magna, heterotopias, macrocerebellum, and periventricular
leukomalacia [56,57].
In instances of fetal overgrowth, macrocephaly and poly-
hydramnios in association with other abnormalities, such as
renal abnormalities, central nervous system abnormalities,
increased NT, and abnormal maternal serum screening results,
a differential diagnosis of Sotos syndrome should be consid-
ered. Examination of the parents for evidence of the Sotos
syndrome phenotype, examination of the family members with
positive Sotos syndrome phenotype, mutational analysis of
NSD1, and molecular cytogenetic analysis of 5q35 micro-
deletion by fluorescence in situ hybridization (FISH) and/or
aCGH are helpful for genetic diagnosis and counseling.
Beckwith-Wiedemann syndrome
Beckwith-Wiedemann syndrome (BWS; OMIM 130650) is
an imprinting disorder. Beckwith [58] andWiedemann [59] first
described an Exomphalos-Macroglossia-Gigantism (EMG)
syndrome that was characterized by the clinical findings of
exomphalos (omphalocele), macroglossia, and gigantism
(macrosomia). Waziri et al [60] first reported two unrelated
children with the features of BWS. In their study, one child
demonstrated duplication of 11p13-p15 and the other demon-
strated duplication of 11p15. They reviewed six other reported
cases with partial dup(11p) and identified the features of BWS.
The region 11p15 contains the genes associated with BWS.
BWS is characterized by macrosomia, ear creases/pits,
macroglossia, omphalocele/umbilical hernia, visceromegaly,
hemihypertrophy, cleft palate, adrenocortical cytomegaly,
renal medullary dysplasia, nephromegaly, nephrocalcinosis,
nephrolithiasis, polyhydramnios, placental mesenchymal
dysplasia, placentomegaly, cardiomegaly, structural cardiac
anomalies, facial nevus flammeus, hemangiomata, neonatal
hypoglycemia, midface hypoplasia, diastasis recti, advanced
bone age, and an increased risk (7.5%) of developing
embryonal tumors such as Wilms tumor, hepatoblastoma,
rhabdomyosarcoma, adrenocortical carcinoma, and neuro-
blastoma [61e65].
BWS is caused by epigenetic alterations or genomic
imbalances at the chromosome 11p15.5 imprinting cluster,
which is functionally divided into domain 1 that contains two
imprinted genesdIGF2 (OMIM 147470; which is expressed
from the paternal allele) and H19 (OMIM 103280; which is
expressed from the maternal allele)dand domain 2 that
contains three imprinted genesdCDKN1C (OMIM 600856;
which is expressed from the maternal allele), KCNQ1 (OMIM
607542; which is expressed from the maternal allele), and
KCNQ1OT1 (OMIM 604115; which is expressed from the
paternal allele). The H19-associated imprinting center 1 (IC1),
or differentially methylated region 1 (DMR1), is usually
methylated on the paternal chromosome and unmethylated on
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imprinting center 2 (IC2), or KvDMR1 or DMR2, is usually
methylated on the maternal chromosome and unmethylated on
the paternal chromosome and in cis it regulates the expression
of the maternally expressed imprinted genes in domain 2
[62,64,65]. Analysis of the frequency of genetic abnormalities
in patients with BWS has determined the following: loss of
methylation at IC2 on the maternal chromosome occurs in
50% of patients; gain of methylation at IC1 on the maternal
chromosome occurs in 5% of patients; CDKN1C mutations
occur in 10% of patients (5% of patients with no family
history of BWS and approximately 40% of patients with
a positive family history of BWS); paternal uniparental dis-
omy (UPD) of 11p15.5 occurs in 20% of patients; duplication,
inversion, or translocation of 11p15.5 occurs in 1% of patients;
and submicroscopic genomic alteration within 11p15.5 occurs
in an unknown percentage of patients [65].
Fetuses with BWS may prenatally manifest with macro-
somia, polyhydramnios, macroglossia, omphalocele, pla-
centomegaly, a long umbilical cord, echogenic kidneys, and
pancreatic cystic dysplasia [66]. Reish et al [67] suggested that
fetal overgrowth, polyhydramnios, enlarged placenta, and
distended abdomen are the constant prenatal findings of BWS.
Williams et al [68] suggested that a diagnosis of BWS can be
reliably made by the presence of either two major criteria
(macroglossia, macrosomia, and abdominal wall defect) or one
major criterion plus two minor criteria (nephromegaly/
dysgenesis, adrenal cytomegaly, aneuploidy/abnormal loci,
and polyhydramnios).
Children conceived by in vitro fertilization (IVF) are at an
increased risk of developing BWS [69]. Halliday et al [69]
suggested that the overall risk of developing BWS in chil-
dren conceived by IVF is about 1 in 4,000 (4 of 14,894), or
nine times greater than that of the general population.
Recently, Gomes et al [70] reported abnormal methylation at
IC2 (KvDMR1 or DMR2) in clinically normal children who
were conceived by assisted reproductive technologies (ARTs).
Hypomethylation at IC2 (KvDMR1 or DMR2) was observed
in 3 of 18 clinically normal children conceived by ARTs (2
conceived by IVF and 1 by intracytoplasmic sperm injection
[ICSI]). Lim et al [71] additionally found that ART may also
be associated with disturbed genomic imprinting in the
imprinting control regions other than 11p15.5, such as DMRs
at 6q24, 7q32, and 15q13. In a study of 25 cases with post-
ART BWS, of which 24 cases had an IC2 epimutation (loss
of methylation at KvDMR1), they found that the loss of
maternal allele methylation at the DMRs at 6q24, 7q32, and
15q13 occurred in 37.5% of post-ART BWS IC2 defect cases
compared with 6.4% of non-ART BWS IC2 defect cases.
Their finding indicates that more generalized DMR hypo-
methylation is more frequent in post-ART BWS cases than
non-ART BWS cases.
In instances of fetal overgrowth, macrocephaly and poly-
hydramnios in association with other abnormalities such as
macroglossia, omphalocele, placentomegaly, enlargement of
the kidneys and adrenal glands, an obstetric history of ART,
a differential diagnosis of BWS should be considered.Examination of the parents for evidence of the BWS pheno-
type, examination of the family members with a positive BWS
phenotype, cytogenetic analysis of 11p15.5 chromosome
aberrations, such as duplication, inversion, or translocation,
mutational analysis of CDKN1C, molecular tests for methyl-
ation and/or copy number changes in chromosome 11p15.5,
such as gain of methylation at H19, loss of methylation at IC2
(KvDMR1 or DMR2), or both, and the UPD test for paternal
UPD 11p15.5 are helpful for genetic diagnosis and counseling.Acknowledgments
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